Evotec SE ranks among the weaker positions in its peer group, with a relatively even profile across the main dimensions. The market setup has weakened, with clear trend damage and relative performance under pressure.
Peer-relative scores, weakest to strongest
Evotec SE is a drug discovery and development platform provider, partnering with pharmaceutical and biotech firms. The company operates globally, integrating AI-driven innovation and offering end-to-end R&D solutions.
Strong revenue growth of 14.5% year-on-year positions Evotec as a clear outlier for topline momentum, but the company’s capital efficiency and risk profile—anchored by a deeply negative ROIC of -11%—keep the discount firmly in place. The core issue is the inability to convert operational scale into value creation, with capital returns persistently in negative territory. This persistent capital return weakness explains why the market continues to price Evotec at a discount, despite its visible growth.
Internally, net income remains negative at -€0.1bn, with a bottom-decile stability score (4/100), and volatility at 58.9%. Revenue growth and the achievement of full-year guidance are positive signals, but they remain secondary to the failure to generate positive earnings or reduce risk. The company’s operational momentum does not translate into financial resilience or a credible path to sustainable profitability. The risk profile—marked by high volatility and ongoing losses—keeps pressure on any rerating scenario.
Recent external context complicates the reading rather than changing it. Management’s ‘Horizon’ transformation and €40m in targeted cost savings indicate active intervention, and AI-driven innovation supports Evotec’s technology leadership. However, these initiatives have yet to show up in profitability or risk metrics. The sector backdrop is challenging, but Evotec’s financial returns remain unproven, and the market is waiting for evidence that operational improvements can break the cycle of capital inefficiency.
Compared to peers, Evotec’s risk and capital return profile is more severe than many. While some sector names also have low profitability, few combine persistent negative ROIC, deep drawdowns, and such high volatility. The company’s growth momentum is positive, but the structural challenges are partly driven by factors specific to Evotec rather than the sector as a whole.
A more constructive read would require ROIC to turn sustainably positive and net income to move out of deeply negative territory. Supporting improvement would include a materially better stability and risk profile, and clear evidence that cost savings translate into profitability. Until then, Evotec appears structurally challenged and priced at a discount for understandable reasons.
Break down EVT.DE's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.